Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Director Dealing

Faron Pharmaceuticals OyAnnouncement

Yesterday 07:15

Faron Pharmaceuticals Ltd | Company announcement | March 19, 2026 at 09:10:00
EET

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company focused on developing novel
immunotherapies, announces today that Juho Jalkanen, CEO of the Company,
subscribed 23,656 ordinary shares in Faron at price of EUR 0.5 per share on 17
March 2026, pursuant to the rights issue announced by the Company on 10 March
2026.

Additionally, Juho Jalkanen subscribed 4,860 ordinary shares in Faron at a
price of EUR 0.5 per share on 17 March 2026 on behalf of persons closely
associated.

Further details are set out in the Notification of Dealing Form below.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             |                                      |
| Kare Laukkanen                      | +358 50 553 9535 / +44 7 469 766 223 |
|                                     | kare.laukkanen@irpartners.fi         |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   | +1 847 791-8085                      |
| (Media)                             | alyssa.paldo@finnpartners.com        |
| Alyssa Paldo                        |                                      |
|                                     |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        | +44 (0) 207 213 0880                 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    | +358 (0)40 555 4727                  |
| (Certified Adviser on Nasdaq First  | +358 (0)50 553 8990                  |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1)
one, upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company’s lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials as
a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com (http://www.faron.com/)

+--------------+-----------------+-----------------+----------+-----------+--+
| Notification |                 |                 |          |           |  |
| of a         |                 |                 |          |           |  |
| Transaction  |                 |                 |          |           |  |
| pursuant to  |                 |                 |          |           |  |
| Article      |                 |                 |          |           |  |
| 19(1) of     |                 |                 |          |           |  |
| Regulation   |                 |                 |          |           |  |
| (EU) No.     |                 |                 |          |           |  |
| 596/2014     |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 1            | Details of the  |                 |          |           |  |
|              | person          |                 |          |           |  |
|              | discharging     |                 |          |           |  |
|              | managerial      |                 |          |           |  |
|              | responsibilities/person |                 |          |           |  |
|              | closely         |                 |          |           |  |
|              | associated/persons |                 |          |           |  |
|              | subject to the  |                 |          |           |  |
|              | notification    |                 |          |           |  |
|              | requirement     |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Name            | Juho Jalkanen   |          |           |  |
|              |                 | Eveliina        |          |           |  |
|              |                 | Jalkanen        |          |           |  |
|              |                 | Esko Jalkanen   |          |           |  |
|              |                 | Aaro Jalkanen   |          |           |  |
|              |                 | Enna Jalkanen   |          |           |  |
|              |                 | Heikki Jalkanen |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 2            | Reason for      |                 |          |           |  |
|              | notification    |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Position/Status | CEO             |          |           |  |
|              |                 | PCA             |          |           |  |
|              |                 | PCA             |          |           |  |
|              |                 | PCA             |          |           |  |
|              |                 | PCA             |          |           |  |
|              |                 | PCA             |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| b.           | Initial         | Initial         |          |           |  |
|              | notification/   | Notification    |          |           |  |
|              | Amendment       |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| c.           | Reference       | 148007/7/4      |          |           |  |
|              | number          |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 3            | Details of the  |                 |          |           |  |
|              | issuer,         |                 |          |           |  |
|              | emission        |                 |          |           |  |
|              | allowance       |                 |          |           |  |
|              | market          |                 |          |           |  |
|              | participant,    |                 |          |           |  |
|              | auction         |                 |          |           |  |
|              | platform,       |                 |          |           |  |
|              | auctioneer or   |                 |          |           |  |
|              | auction monitor |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Name            | Faron           |          |           |  |
|              |                 | Pharmaceuticals |          |           |  |
|              |                 | Ltd.            |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| b.           | LEI             |                 |          |           |  |
|              |                 | 7437009H31TO1DC0EB42 |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 4            | Details of the  |                 |          |           |  |
|              | transaction(s): |                 |          |           |  |
|              | section to be   |                 |          |           |  |
|              | repeated for    |                 |          |           |  |
|              | (i) each type   |                 |          |           |  |
|              | of instrument;  |                 |          |           |  |
|              | (ii) each type  |                 |          |           |  |
|              | of transaction; |                 |          |           |  |
|              | (iii) each      |                 |          |           |  |
|              | date; and (iv)  |                 |          |           |  |
|              | each place      |                 |          |           |  |
|              | where           |                 |          |           |  |
|              | transactions    |                 |          |           |  |
|              | have been       |                 |          |           |  |
|              | conducted       |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Description of  | Share           |          |           |  |
|              | the financial   |                 |          |           |  |
|              | instrument,     |                 |          |           |  |
|              | type of         | ISIN:           |          |           |  |
|              | instrument      | FI4000153309    |          |           |  |
|              |                 |                 |          |           |  |
|              | Identification  |                 |          |           |  |
|              | Code            |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| b.           | Nature of the   | Subscription    |          |           |  |
|              | transaction     |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
|              |                 |                 | Price(s) | Volume(s) |  |
|              |                 |                 | per      |           |  |
|              |                 |                 | share    |           |  |
|              |                 |                 | (p)      |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
|              |                 |                 | EUR 0.5  | 23,796    |  |
|              |                 |                 | EUR 0.5  | 1,377     |  |
|              |                 |                 | EUR 0.5  | 684       |  |
|              |                 |                 | EUR 0.5  | 1,431     |  |
|              |                 |                 | EUR 0.5  | 684       |  |
|              |                 |                 | EUR 0.5  | 684       |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
|              |                 |                 |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| d.           | Aggregated      |                 |          |           |  |
|              | information     |                 |          |           |  |
|              | Volume          | Transaction     |          |           |  |
|              | Price           | details (a)     |          |           |  |
|              |                 | (1): Volume     |          |           |  |
|              |                 | 23,796 Unit     |          |           |  |
|              |                 | price: 0.5 EUR  |          |           |  |
|              |                 | (2): Volume     |          |           |  |
|              |                 | 1,377 Unit      |          |           |  |
|              |                 | price: 0.5 EUR  |          |           |  |
|              |                 | (1): Volume 684 |          |           |  |
|              |                 | Unit price: 0.5 |          |           |  |
|              |                 | EUR             |          |           |  |
|              |                 | (1): Volume     |          |           |  |
|              |                 | 1,431 Unit      |          |           |  |
|              |                 | price: 0.5 EUR  |          |           |  |
|              |                 | (1): Volume 684 |          |           |  |
|              |                 | Unit price: 0.5 |          |           |  |
|              |                 | EUR             |          |           |  |
|              |                 | (1): Volume 684 |          |           |  |
|              |                 | Unit price: 0.5 |          |           |  |
|              |                 | EUR             |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| e.           | Date of the     | 17.3.2026       |          |           |  |
|              | transaction     | (outside a      |          |           |  |
|              |                 | trading venue)  |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| f.           | Venue           | Nasdaq First    |          |           |  |
|              |                 | North Growth    |          |           |  |
|              |                 | Market          |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+